This article examines the evidence, symptoms to watch for, and practical guidance for patients and healthcare providers navigating pancreatic safety concerns
Beyond pharmacotherapy, emerging evidence suggests that gut microbiotaderived metabolites and postbiotics, such as short-chain fatty acids (SCFAs) and tryptophan-derived indoles, can modulate enteroendocrine function, inflammatory tone, insulin sensitivity, and gutbrain communication
We are looking at very specific metabolic markers
The most common adverse reactions include nausea, vomiting, diarrhea/constipation, abdominal pain, decreased appetite, etc
Most patients begin with a low dose thats gradually increased to minimize these effects and allow the body to acclimate